W
Winifred W. Prosise
Researcher at Merck & Co.
Publications - 28
Citations - 1314
Winifred W. Prosise is an academic researcher from Merck & Co.. The author has contributed to research in topics: Protease & Binding site. The author has an hindex of 12, co-authored 28 publications receiving 1157 citations. Previous affiliations of Winifred W. Prosise include Schering-Plough.
Papers
More filters
Journal ArticleDOI
Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease–helicase
TL;DR: The scNS3-NS4A structure provides the first atomic view of polyprotein cis processing, and suggests autoinhibition and substrate-induced activation mechanisms for regulation of NS3 protease activity.
Journal ArticleDOI
Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab.
Giovanna Scapin,Xiaoyu Yang,Winifred W. Prosise,Mark A. McCoy,Paul Reichert,Jennifer M. Johnston,Ramesh S. Kashi,Corey Strickland +7 more
TL;DR: The structure of the human full-length IgG4 S228P anti-PD1 antibody pembrolizumab is reported, and this unusual Fc conformation suggests possible structural diversity between IgG subclasses and shows that use of isolated antibody fragments could mask potentially important interactions, owing to molecular flexibility.
Journal ArticleDOI
Structure of the insulin receptor-insulin complex by single-particle cryo-EM analysis.
Giovanna Scapin,Venkata P. Dandey,Zhening Zhang,Winifred W. Prosise,Alan Hruza,Theresa M. Kelly,Todd Mayhood,Corey Strickland,Clinton S. Potter,Bridget Carragher +9 more
TL;DR: Reconstructions of single-particle cryo-electron microscopy reconstructions of the insulin receptor ECD dimer with insulin suggest that recruitment of the α-CT helix upon binding of the first insulin changes the relative subdomain orientations and triggers downstream signal propagation.
Journal ArticleDOI
Construction, expression, and characterization of a novel fully activated recombinant single‐chain hepatitis C virus protease
S. Shane Taremi,Brian M. Beyer,Maureen Maher,Nanhua Yao,Winifred W. Prosise,Patricia C. Weber,Bruce A. Malcolm +6 more
TL;DR: A single‐chain recombinant form of the protease has been constructed in which NS4A residues 21‐32 were fused in frame to the amino terminus of the NS3 protease domain (residues 3ndash181) through a tetrapeptide linker.
Journal ArticleDOI
Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
Andrew Prongay,Zhuyan Guo,Nanhua Yao,John Pichardo,Thierry O. Fischmann,Corey Strickland,Joseph E. Myers,Patricia C. Weber,Brian M. Beyer,Richard N. Ingram,Zhi Hong,Winifred W. Prosise,Lata Ramanathan,S. Shane Taremi,Taisa Yarosh-Tomaine,Rumin Zhang,Mary M. Senior,Rong-Sheng Yang,Bruce A. Malcolm,Ashok Arasappan,Frank Bennett,Stephane L. Bogen,Kevin X. Chen,Edwin Jao,Yi-Tsung Liu,Raymond G. Lovey,Anil K. Saksena,Srikanth Venkatraman,Viyyoor M. Girijavallabhan,F. George Njoroge,Vincent Madison +30 more
TL;DR: The structures of both the native holo-HCV NS3/4A proteasedomain and the protease domain with a serine 139 to alanine (S139A) mutation were solved to high resolution and correlated with changes in the buried surface area upon binding the inhibitor to the active site.